Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F25%3A43928629" target="_blank" >RIV/00064173:_____/25:43928629 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60460709:41210/25:101903 RIV/00216208:11120/25:43928629

Výsledek na webu

<a href="https://doi.org/10.3390/cancers17132238" target="_blank" >https://doi.org/10.3390/cancers17132238</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cancers17132238" target="_blank" >10.3390/cancers17132238</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma

Popis výsledku v původním jazyce

The oral microbiome is the largest and most diverse microbiome in the human body, second only to the gut microbiome. Mounting evidence supports its role in the genesis, promotion, and aggressiveness of oral cancer as well as certain cancers of distant sites. In this review, we focus on describing specific microbial alterations, which were proven to be associated either with head and neck squamous cell carcinoma (HNSCC) development or with its treatment efficacy, especially with radiotherapy, chemotherapy, targeted treatment, and immunotherapy. Purpose: To discuss associations of oral and gut microbiome with the development of HNSCC and with its anti-cancer treatment efficacy. Methods: A literature search was conducted in PubMed/Medline. Due to the nature of this narrative review, we prioritized the most recent studies. Regarding the type of studies, umbrella reviews, meta-analyses, and systematic reviews were prioritized, in that order, over individual studies. Results: The microbiome plays an important role in cancer development, progression, and treatment response across solid tumors, including HNSCC. Better treatment response and/or reduction in treatment toxicities can be achieved through microbiome alteration; e.g., the use of specific probiotics can result in a reduction in acute radiotherapy-induced mucositis in HNSCC radiotherapy, and fecal microbiota transplantation from immune-checkpoint inhibitor (ICI) responders to non-responders can overcome primary resistance to ICI. Conclusions: We highlighted specific research areas on how to utilize microbiome modification to enhance anti-cancer treatment response and/or decrease the incidence and severity of anti-cancer treatment toxicities.

Název v anglickém jazyce

Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma

Popis výsledku anglicky

The oral microbiome is the largest and most diverse microbiome in the human body, second only to the gut microbiome. Mounting evidence supports its role in the genesis, promotion, and aggressiveness of oral cancer as well as certain cancers of distant sites. In this review, we focus on describing specific microbial alterations, which were proven to be associated either with head and neck squamous cell carcinoma (HNSCC) development or with its treatment efficacy, especially with radiotherapy, chemotherapy, targeted treatment, and immunotherapy. Purpose: To discuss associations of oral and gut microbiome with the development of HNSCC and with its anti-cancer treatment efficacy. Methods: A literature search was conducted in PubMed/Medline. Due to the nature of this narrative review, we prioritized the most recent studies. Regarding the type of studies, umbrella reviews, meta-analyses, and systematic reviews were prioritized, in that order, over individual studies. Results: The microbiome plays an important role in cancer development, progression, and treatment response across solid tumors, including HNSCC. Better treatment response and/or reduction in treatment toxicities can be achieved through microbiome alteration; e.g., the use of specific probiotics can result in a reduction in acute radiotherapy-induced mucositis in HNSCC radiotherapy, and fecal microbiota transplantation from immune-checkpoint inhibitor (ICI) responders to non-responders can overcome primary resistance to ICI. Conclusions: We highlighted specific research areas on how to utilize microbiome modification to enhance anti-cancer treatment response and/or decrease the incidence and severity of anti-cancer treatment toxicities.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancers

ISSN

2072-6694

e-ISSN

2072-6694

Svazek periodika

17

Číslo periodika v rámci svazku

13

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

30

Strana od-do

2238

Kód UT WoS článku

001526122100001

EID výsledku v databázi Scopus

2-s2.0-105010619106